FDA officials tout steady growth in biosimilar program, enhancements under FDORA
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesChemistry, Manufacturing and Controls (CMC)Clinical TrialsComplianceNorth AmericaRegulatory Intelligence/Policy